Lithuania Pharmaceuticals and Healthcare Report Q1 2016

78 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Lithuania’s pharmaceutical and healthcare market represents a modest prospect for investment
from multinational firms. Increasing demand due to a rising burden of chronic disease will translate to an
increase in sales; however, fiscal policies and the small size of the market will limit revenue earning
opportunities.
Headline Expenditure Projections
? Pharmaceuticals: EUR601mn (USD806mn) in 2014 to EUR616mn (USD677mn) in 2015; +2.4% in
local currency terms and -16.0% in US dollar terms. Forecast revised downwards from Q215.
? Healthcare: EUR2.14bn (USD2.87bn) in 2014 to EUR2.14bn (USD2.36bn) in 2015; +0.1% in local
currency terms and -17.8% in US dollar terms. Forecast revised downwards from Q215.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Lithuania 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Lithuania 2013-2019) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2013-2019) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2013-2019) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2013-2019) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lithuania 2011-2019) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lithuania 2011-2019) 19
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Lithuania 2013-2019) 21
OTC Market Forecast 22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Lithuania 2013-2019) 23
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (Lithuania 2013-2019) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (Lithuania 2013-2019) 26
Industry Risk Reward Index 27
Central And Eastern Europe Risk/Reward Index - Q1 2016 27
Lithuania Risk/Reward Index 34
Rewards 34
Risks 34
Regulatory Review 36
Intellectual Property Regime 39
Pricing Regime 39
Table: Wholesale Mark-Ups For Reimbursed And Non-Reimbursed Medicines 40
Reimbursement Regime 41
Table: Retail Mark-Ups For Reimbursed And Non-Reimbursed Medicines 42
Market Overview 44
Healthcare Sector 45
Table: Healthcare Resources (Lithuania 2009-2014) 46
Table: Healthcare Personnel (Lithuania 2009-2014) 46
Table: Healthcare Activity (Lithuania 2009-2014) 47
Research & Development 48
Clinical Trials 50
Epidemiology 51
Table: Leading Causes of Death, 2005-2013 51
Table: Incidence of HIV & AIDS, 2002-2010 53
Competitive Landscape 54
Research-Based Industry 54
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA) 54
Table: Multinational Market Activity 55
Generic Drugmakers 55
Pharmaceutical Distribution 56
Pharmaceutical Retail Sector 57
Company Profile 59
Valentis 59
Sanitas (Valeant) 61
Sicor Biotech (Teva) 64
Demographic Forecast 67
Table: Population Headline Indicators (Lithuania 1990-2025) 68
Table: Key Population Ratios (Lithuania 1990-2025) 68
Table: Urban/Rural Population & Life Expectancy (Lithuania 1990-2025) 69
Table: Population By Age Group (Lithuania 1990-2025) 69
Table: Population By Age Group % (Lithuania 1990-2025) 70
Glossary 72
Methodology 74
Pharmaceutical Expenditure Forecast Model 74
Healthcare Expenditure Forecast Model 74
Notes On Methodology 75
Risk/Reward Index Methodology 76
Index Overview 77
Table: Pharmaceutical Risk/Reward Index Indicators 77
Indicator Weightings 78

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Lithuania 2013-2019)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Lithuania 2013-2019)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2013-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2013-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2013-2019)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lithuania 2011-2019)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lithuania 2011-2019)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Lithuania 2013-2019)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Lithuania 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts (Lithuania 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts local currency (Lithuania 2013-2019)
Table: Wholesale Mark-Ups For Reimbursed And Non-Reimbursed Medicines
Table: Retail Mark-Ups For Reimbursed And Non-Reimbursed Medicines
Table: Healthcare Resources (Lithuania 2009-2014)
Table: Healthcare Personnel (Lithuania 2009-2014)
Table: Healthcare Activity (Lithuania 2009-2014)
Table: Leading Causes of Death, 2005-2013
Table: Incidence of HIV & AIDS, 2002-2010
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA)
Table: Multinational Market Activity
Table: Population Headline Indicators (Lithuania 1990-2025)
Table: Key Population Ratios (Lithuania 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Lithuania 1990-2025)
Table: Population By Age Group (Lithuania 1990-2025)
Table: Population By Age Group % (Lithuania 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Lithuania Pharmaceuticals and Healthcare Report Q2 2016BMI View: Lithuania's pharmaceutical and healthcare market represents a modest prospect for investment from multinational firms. Increasing demand due to a rising burden of chronic disease will translate to an increase in sales; however, fiscal policies and the small size of the market will limit revenue earning opportunities. Headline Expenditure Projections ? Pharmaceuticals: EUR616mn (USD677mn) in 2015 to EUR638mn (USD682mn) in 2016; +3.6% in local currency terms and 0.7% in US […]
  • Switzerland Pharmaceuticals and Healthcare Report Q4 2014BMI View: Most of Switzerland's demographic and economic indicators are favourable towards increased pharmaceutical and healthcare spending. The proportion of the pensionable population is high and growing, and this will translate into greater demand for drugs. Furthermore, the country's highly developed infrastructure means that access to healthcare is easy, further supporting the consumption of medicines. Headline Expenditure Projections ? Pharmaceuticals: CHF7.06bn (USD7.68bn) in […]
  • Lithuania Pharmaceuticals and Healthcare Report Q4 2015BMI View: Non-communicable conditions such as cardiovascular disease and cancer will continue to be the primary contributors to Lithuania's disease burden. Although these disease dynamics will make the country attractive to innovative drugmakers, the small size of the country's population will limit the commercial opportunity. The absolute disease burden is expected to decline over the next 15 years as the standard of healthcare improves and the population contracts. Headline […]
  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality […]
  • Slovakia Pharmaceuticals and Healthcare Report Q1 2016BMI View: Despite Slovakia's declining disease burden, multinational drugmakers will continue to target the country given the sizeable proportion of non-communicable diseases. Slovakia's cardiovascular drug market will prove to be the most lucrative, with cardiovascular diseases accounting for over half of deaths and the highest share of drug spending. Headline Expenditure Projections ? Pharmaceuticals: EUR1.85bn (USD2.46bn) in 2014 to EUR1.91bn (USD2.10bn) in 2015; +3.5% in local […]